☆ 3.8 Article

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

JAC-ANTIMICROBIAL RESISTANCE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Public, Environmental & Occupational Health

Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: A multicenter before-and-after cross-sectional study

Renato Pascale et al.

Summary: This study assessed the incidence of colonization and infection with CPE and CR-Ab in ICUs before and during the COVID-19 pandemic. The results showed no significant change in CPE colonization and infection, but a significant increase in CR-Ab colonization and infection. The CR-Ab strains belonged to the same clonal lineage and horizontal transmission was observed. Therefore, infection control activities should be conducted during the pandemic and adjusted according to the situation.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)

添加到收藏夹

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Editorial Material Infectious Diseases

Cefiderocol: the Trojan horse has arrived but will Troy fall?

Emily L. Heil et al.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study

Mario Tumbarello et al.

Summary: The study found that there was no significant difference in 30-day mortality rates between patients treated with ceftazidime-avibactam alone and those treated with combination regimens for managing infections caused by carbapenem-resistant Enterobacteriaceae. Factors such as septic shock and neutropenia at infection onset were positively associated with mortality, while prolonged infusion of CAZ-AVI was negatively associated with mortality. Further research is needed to explore the potential survival benefits of prolonging CAZ-AVI infusions in certain types of infections.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence

Corrado Pelaia et al.

Summary: The article discusses the rationale for using tocilizumab in the SARS-CoV-2-induced cytokine storm, current evidence, and future perspectives, focusing on its therapeutic effects in patients with life-threatening SARS-CoV-2 infection.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens

Anselm Jorda et al.

Summary: The increasing resistance of gram-negative bacteria necessitates effective antibiotics, and Cefiderocol, a siderophore cephalosporin, offers a promising solution in combating resistant pathogens. Comprehensive studies have shown its efficacy against various gram-negative pathogens with limited resistance, making it a viable treatment option for patients with gram-negative infections. In clinical trials, Cefiderocol demonstrated non-inferiority in treating complicated urinary tract infections and nosocomial pneumonia compared to carbapenems, and showed similarity in efficacy against carbapenem-resistant gram-negative pathogens when compared to the best available therapy.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Immunology

Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature

Sandra Zingg et al.

Open Forum Infectious Diseases (2020)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Infectious Diseases

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii

Alessandra Oliva et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020

Stephen Perez et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)

添加到收藏夹

Review Infectious Diseases

Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment

E. -T. Piperaki et al.

CLINICAL MICROBIOLOGY AND INFECTION (2019)

添加到收藏夹

Letter Infectious Diseases

Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report

Enrico Maria Trecarichi et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

添加到收藏夹

Article Infectious Diseases

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

Alessandro Cassini et al.

LANCET INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Infectious Diseases

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli et al.

LANCET INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Microbiology

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

Meredith A. Hackel et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

添加到收藏夹

Article Medicine, General & Internal

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Public, Environmental & Occupational Health

CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting

Teresa C. Horan et al.

AMERICAN JOURNAL OF INFECTION CONTROL (2008)

添加到收藏夹

Article Medicine, General & Internal

Health care-associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections

ND Friedman et al.

ANNALS OF INTERNAL MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.